My Companies
Notification
Account
Log Out
Login
Cipla received USFDA approval for generic Advair Diskus (fluticasone/salmeterol) in all strengths. US market size ~$908M; first DPI approval from its US network. Launch expected Q2 FY27, a key catalyst for US respiratory growth.
Cipla Partners With Qilu To License Keytruda Biosimilar In US
Cipla Signs Exclusive License With SBP For TQB2102 HER2 ADC
Cipla Receives VAI Classification For InvaGen New York Inspection
Cipla Receives Seven Form 483 Observations At Pithampur Facility
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role